PROBLEMS IN THE THERAPY OF AXIAL SPONDYLOARTHRITIS IN THE PROCEEDINGS OF THE EULAR CONGRESS 2015 (ROME, 10–13 JUNE 2015)

Abstract

The Congress considered the issues pertinent to the latest approaches to therapy for axial spondyloarthritis (axSpA), as well as the problems associated with a search for axSpA-modifying anti-rheumatic drugs. Reports on the results of therapy with nonsteroidal anti-inflammatory drugs and biological agents (tumor necrosis factor-α and interleukin 17/23 inhibitors) were of the most relevance.

Keywords

• axial spondyloarthritis
• nonsteroidal anti-inflammatory drugs
• biological agents
• tumor necrosis factor-α inhibitors
• interleukin 17/23